Ann: Expanded Heart Protection Discovery for Zantrene, page-290

All good, mate.

It's certainly going to be an exciting 36-months watching this space develop.

I understand what you are saying, JD. You always raise great points of discussion. I suspect a phase 1/2 clinical trial investigating the efficacy and cardio-safety of Zan+Car in MM patients will include patients who are and are not sensitive to Zan via a CDx. A clinical trial like this will provide RAC (and a purchaser) some indication of the patient population in which Zan+Car is most effective. If there is a patient population that is not suitable, then the data will show that. Let's say, for example, that a patient does not respond and their cancer gets worse. RAC can cross check patient responses to CDx, or maybe some other information gathered during the trial.

We just have to wait and see!